candesartan cilexetil has been researched along with Alloxan Diabetes in 9 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
| Excerpt | Relevance | Reference |
|---|---|---|
| "Candesartan cilexetil treatment improved cardiac structural remodeling and cardiac function in SDT rats." | 5.35 | Long-term angiotensin II blockade may improve not only hyperglycemia but also age-associated cardiac fibrosis. ( Fukumoto, M; Hayashi, T; Ikeda, T; Jin, D; Kitaura, Y; Miyazaki, M; Oku, H; Sugiyama, T; Takai, S, 2009) |
| " Candesartan cilexetil (TCV-116), a potent angiotensin II (AII) receptor antagonist, has beneficial effects on hypertension as well as on heart, renal and cerebrovascular disease." | 3.71 | The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats. ( Nagisa, Y; Nakagawa, S; Shintani, A, 2001) |
| "Many models of diabetic nephropathy have been reported." | 1.38 | A novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment. ( Fujita, A; Morito, N; Ojima, M; Okamura, M; Shimohata, H; Takahashi, S; Yamagata, K; Yoh, K, 2012) |
| "Candesartan cilexetil treatment improved cardiac structural remodeling and cardiac function in SDT rats." | 1.35 | Long-term angiotensin II blockade may improve not only hyperglycemia but also age-associated cardiac fibrosis. ( Fukumoto, M; Hayashi, T; Ikeda, T; Jin, D; Kitaura, Y; Miyazaki, M; Oku, H; Sugiyama, T; Takai, S, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kang, MK | 1 |
| Chung, WB | 1 |
| Hong, SK | 1 |
| Kim, OR | 1 |
| Ihm, SH | 1 |
| Chang, K | 1 |
| Seung, KB | 1 |
| Chow, BS | 1 |
| Koulis, C | 1 |
| Krishnaswamy, P | 1 |
| Steckelings, UM | 1 |
| Unger, T | 1 |
| Cooper, ME | 1 |
| Jandeleit-Dahm, KA | 1 |
| Allen, TJ | 1 |
| Jin, D | 1 |
| Takai, S | 1 |
| Sugiyama, T | 1 |
| Hayashi, T | 1 |
| Fukumoto, M | 1 |
| Oku, H | 1 |
| Kitaura, Y | 1 |
| Ikeda, T | 1 |
| Miyazaki, M | 1 |
| Ozdemir, S | 1 |
| Tandogan, B | 1 |
| Ulusu, NN | 1 |
| Turan, B | 1 |
| Fujita, A | 1 |
| Yoh, K | 1 |
| Shimohata, H | 1 |
| Morito, N | 1 |
| Ojima, M | 1 |
| Okamura, M | 1 |
| Takahashi, S | 1 |
| Yamagata, K | 1 |
| Horio, N | 1 |
| Clermont, AC | 1 |
| Abiko, A | 1 |
| Abiko, T | 1 |
| Shoelson, BD | 1 |
| Bursell, SE | 1 |
| Feener, EP | 1 |
| Kakizawa, H | 1 |
| Itoh, Y | 1 |
| Imamura, S | 1 |
| Matsumoto, T | 1 |
| Ishiwata, Y | 1 |
| Ono, Y | 1 |
| Yamamoto, K | 1 |
| Kato, T | 1 |
| Hayakawa, N | 1 |
| Oda, N | 1 |
| Goto, Y | 2 |
| Nagasaka, A | 1 |
| Senda, T | 1 |
| Itoh, M | 1 |
| Nakamura, H | 1 |
| Inoue, T | 1 |
| Arakawa, N | 1 |
| Shimizu, Y | 1 |
| Yoshigae, Y | 1 |
| Fujimori, I | 1 |
| Shimakawa, E | 1 |
| Toyoshi, T | 1 |
| Yokoyama, T | 1 |
| Nagisa, Y | 1 |
| Shintani, A | 1 |
| Nakagawa, S | 1 |
9 other studies available for candesartan cilexetil and Alloxan Diabetes
| Article | Year |
|---|---|
Effects of candesartan cilexetil and amlodipine orotate on receptor for advanced glycation end products expression in the aortic wall of Otsuka Long-Evans Tokushima Fatty (OETFF) type 2 diabetic rats.
Topics: Amlodipine; Animals; Aorta; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Experimental; Dia | 2016 |
The angiotensin II type 2 receptor agonist Compound 21 is protective in experimental diabetes-associated atherosclerosis.
Topics: Angiotensin II Type 2 Receptor Blockers; Animals; Apolipoproteins E; Atherosclerosis; Benzimidazoles | 2016 |
Long-term angiotensin II blockade may improve not only hyperglycemia but also age-associated cardiac fibrosis.
Topics: Aging; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; An | 2009 |
Angiotensin II receptor blockage prevents diabetes-induced oxidative damage in rat heart.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Benzimidazoles; | 2009 |
A novel diabetes mellitus mouse model, MAFA-deficient and beta cell-specific MAFK-overexpressing hybrid transgenic mice, developed severe diabetic nephropathy and improved with TCV-116 (candesartan cilexetil) treatment.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphe | 2012 |
Angiotensin AT(1) receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodilatation in normotensive diabetic rats.
Topics: Acetylcholine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; An | 2004 |
Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
Topics: Albuminuria; Analysis of Variance; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme I | 2004 |
Pharmacological and pharmacokinetic study of olmesartan medoxomil in animal diabetic retinopathy models.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Area Under Curve; Benzimidazoles; Biphenyl Compoun | 2005 |
The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats.
Topics: Angiotensin Receptor Antagonists; Animals; Benzimidazoles; Biphenyl Compounds; Blood Glucose; Blood | 2001 |